IL6 and melanoma: A vaccine composed of Hyper-IL6 (H16) gene-modified melanoma cells admixed with allogenic iPSCs was shown to cause superior extension disease-free survival, and long-term overall survival in melanoma-challenged C57BL/6 mice when compared to modified cells alone or H16 modified cells plus ESCs [117] (Table 1).